Journal of Inherited Metabolic Disease

, Volume 18, Issue 4, pp 435–447 | Cite as

Adrenoleukodystrophy: natural history, treatment and outcome

  • H. W. Moser
Komrower Lecture


Our laboratory has identified nearly 2000 patients with X-linked adrenoleukodystrophy (ALD) and conducted therapeutic trials in groups of patients who represent the major phenotypes. We report recent results of dietary therapy with a mixture of glyceryl trioleate and glyceryl trierucate oil, also referred to as Lorenzo's Oil, in the asymptomatic and childhood cerebral phenotypes. Fifty-three patients started this therapy at a mean age of 7.5 years at a time when they were free of neurological symptoms. Although analysis of data is hampered by the lack of a concurrent control group, follow-up studies after 39 months of therapy suggest that subsequent neurological involvement was less frequent and less severe than anticipated from historical controls. Retrospective analysis of the effect of the oil in patients with the severe childhood cerebral phenotype indicates that there was a slight but statistically significant slowing of clinical progression and delay of death.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams RD, Kubik CS (1952) The morbid anatomy of the demyelinative diseases.Am J Med 12: 510–546.Google Scholar
  2. Aubourg P, Blanche S, Jambaque I, et al (1990) Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation.N Engl J Med 322: 1860–1866.Google Scholar
  3. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, et al (1993) A two-year trial of oleic and erucic acids (‘Lorenzo's oil’) as treatment for adrenomyeloneuropathy.N Engl J Med 329: 745–752.Google Scholar
  4. Boles DJ, Craft DA, Padgett DA, Loria RM, Rizzo WB (1991) Clinical variation in X-linked adrenoleukodystrophy — fatty acid and lipid metabolism in cultured fibroblasts.Biochem Med Metab Biol 45: 74–91.Google Scholar
  5. Bourre JM, Dumont OS, Piciotti MJ, Pascal GA, Durand GA (1992) Dietary alpha-linolenic acid deficiency in adult rats for 7 months does not alter brain docosahexaenoic acid content, in contrast to liver, heart and testes.Biochim Biophys Acta 1124: 119–122.Google Scholar
  6. Brown III FR, Van Duyn MA, Moser AB, et al (1982) Adrenoleukodystrophy: Effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids.Johns Hopkins Med J 151: 164–172.Google Scholar
  7. Griffin DE, Moser HW, Mendoza Q, Moench T, O'Toole S, Moser AB (1985) Identification of the inflammatory cells in the nervous system of patients with adrenoleukodystrophy.Ann Neurol 18: 660–664.Google Scholar
  8. Higgins CF, Gallagher MP, Mimmack ML, Pearce SR (1988) A family of closely related ATP-binding subunits from prokaryotic and eukaryotic cells.Bioessays 8: 111–116.Google Scholar
  9. Igarashi M, Shaumburg HH, Powers J, Kishimoto Y, Kolodny E, Suzuki K (1976) Fatty acid abnormality in adrenoleukodystrophy.J Neurochem 26: 851–860.Google Scholar
  10. Kaplan PW, Tusa RJ, Shankroff J, Heller JE, Moser HW (1993) Visual evoked potentials in adrenoleukodystrophy: A trial with Lorenzo oil.Ann Neurol 34: 169–174.Google Scholar
  11. Kishimoto Y, Moser HW, Kawamura N, Platt M, Pallante B, Fenselau C (1980) Evidence that abnormal very long chain fatty acids of brain cholesterol esters are of exogenous origin.Biochem Biophys Res Commun 96: 69–76.Google Scholar
  12. Knazek RA, Rizzo WB, Schulman JD, Dave JR (1983) Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy.J Clin Invest 72: 245–248.Google Scholar
  13. Krivit W, Shapiro E, Lockman L, Torres F, Stillman A, Moser A, Moser H (1992) Recommendations for treatment of childhood cerebral form of adrenoleukodystrophy. In Hobbs JR, Riches PG, eds.Correction of Certain Genetic Diseases by Transplantation. London: COGENT Trust, 38–49.Google Scholar
  14. Lazo O, Contreras M, Bhushan A, Stanley W, Singh I (1989) Adrenoleukodystrophy: Impaired oxidation of fatty acids due to peroxisomal lignoceroyl-CoA ligase deficiency.Arch Biochem Biophys 270: 722–728.Google Scholar
  15. Loes DJ, Hite S, Moser HW, et al (1994) Adrenoleukodystrophy: Development of a scoring method for brain MR observations.Am J Neuroradiol 15: 1761–1766.Google Scholar
  16. Migeon BR, Moser HW, Moser AB, Axelman J, Sillence D, Norum RA (1981) Adrenoleukodystrophy: Evidence for X-linkage, inactivation and selection favoring the mutant allele in heterozygous cells.Proc Natl Acad Sci USA 78: 5066–5070.Google Scholar
  17. Moser HW, Moser AB (1991) Measurements of saturated very long chain fatty acids in plasma. In Hommes F, ed.Techniques in Diagnostic Human Biochemical Genetics. New York: Wiley-Liss, 177–191.Google Scholar
  18. Moser AB, Borel J, Odone A, et al (1987) A new dietary therapy for adrenoleukodystrophy: Biochemical and preliminary clinical results in 36 patients.Ann Neurol 21: 240–249.Google Scholar
  19. Moser HW, Aubourg P, Cornblath D, et al (1991) The therapy for X-linked adrenoleukodystrophy. In Desnick RJ, ed.Treatment of Genetic Diseases. New York: Churchill Livingstone, chap. 7, 111–129.Google Scholar
  20. Moser HW, Moser AB, Smith KD, et al (1992) Adrenoleukodystrophy: Phenotypic variability: Implications for therapy.J Inher Metab Dis 15: 645–664.Google Scholar
  21. Moser HW, Kok F, Neumann S, et al (1994) Adrenoleukodystrophy update: Genetics and effect of Lorenzo's oil therapy in asymptomatic patients.Int J Pediatr 9: 196–204.Google Scholar
  22. Mosser J, Douar AM, Sarde CO, et al (1993) Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters.Nature 361: 726–730.Google Scholar
  23. Odone A, Odone M (1989) Lorenzo's oil. A new treatment for adrenoleukodystrophy.J Pediatr Neurosci 5: 55–61.Google Scholar
  24. Paty DW, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis.Neurology 43: 662–667.Google Scholar
  25. Poulos A, Gibson R, Sharp P, Beckman K, Grattan-Smith P (1994) Very long chain fatty acids in brain after treatment with Lorenzo's Oil.Ann Neurol 36: 741–746.Google Scholar
  26. Powers JM (1985) Adrenoleukodystrophy (Adreno-testiculo-leuko-myelo-neuropathic complex).Clin Neuropathol 4: 181–199.Google Scholar
  27. Powers JM, Liu Y, Moser A, Moser H (1992) The inflammatory myelinopathy of adrenoleuko-dystrophy: Cells, effector molecules, and pathogenetic implications.J Neuropathol Exp Neurol 51: 630–643.Google Scholar
  28. Rasmussen M, Moser AB, Borel J, Khangoora S, Moser HW (1994) Brain, liver and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's Oil).Neurochem Res 19: 1073–1082.Google Scholar
  29. Refsum S (1981) Heredopathia atactica polyneuritiformis: Phytanic-acid disease, Refsum's disease: A biochemically well-defined disease with a specific dietary treatment.Arch Neurol 38: 605–606.Google Scholar
  30. Rizzo WB, Watkins PA, Phillips MW, Cranin D, Campbell B, Avigan J (1986) Adrenoleukodystrophy: Oleic acid lowers fibroblast saturated C22–C26 fatty acids.Neurology 36: 357–361.Google Scholar
  31. Rizzo WB, Phillips MW, Dammann AL, Leshner RY, Jennings SVK (1987) Adrenoleukodystrophy: Dietary oleic acid lowers hexacosanoate levels.Ann Neurol 21: 232–239.Google Scholar
  32. Rizzo WB, Leshner RT, Odone A, et al (1989) Dietary erucic acid therapy for X-linked adrenoleukodystrophy.Neurology 39: 1415–1422.Google Scholar
  33. Rizzo WB, Leshner RT, Odone A, et al (1990) X-linked adrenoleukodystrophy: Biochemical and clinical efficacy of dietary erucic acid therapy. In Uziel G, Wanders RJA, Cappa M, eds.Adrenoleukodystrophy and Other Peroxisomal Disorders. International Congress Series 898. Amsterdam: Excerpta Medica, 149–162.Google Scholar
  34. Sadeghi-Nejad A, Senior B (1990) Adrenomyeloneuropathy presenting as Addison's disease in childhood.N Engl J Med 322: 13–16.Google Scholar
  35. Sarde CO, Mosser J, Kioschis P, et al (1994) Genomic organization of the adrenoleukodystrophy gene.Genomics 22: 13–20.Google Scholar
  36. Schaumburg HH, Powers JM, Raine CS, Suzuki K, Richardson EP (1975) Adrenoleukodystrophy: A clinical and pathological study of 17 cases.Arch Neurol 33: 577–591.Google Scholar
  37. Shapiro EG, Klein KA (1994) Dementia in childhood: Issues in neuropsychological assessment with application to the natural history and treatment of degenerative storage diseases. In Tramontana MG, Hooer SR, eds.Advances in Child Neuropsychology. New York: Springer Verlag; 119–171.Google Scholar
  38. Siemerling E, Creutzfeldt HG (1923) Bronzekrankheit und sklerosierende encephalomyelitis.Arch Psychiatr Nervenkr 68: 217–244.Google Scholar
  39. Singh I, Moser AB, Moser HW, Kishimoto Y (1984a) Adrenoleukodystrophy: Impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts and amniocytes.Pediatr Res 18: 286–290.Google Scholar
  40. Singh I, Moser AB, Goldfischer S, Moser HW (1984b) Lignoceric acid is oxidized in the peroxisomes: Implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy.Proc Natl Acad Sci USA 81: 4203–4207.Google Scholar
  41. Tsuji S, Sano-Kawamura T, Ariga T, Miyatake T (1985) Metabolism of (17,18-3H2) hexacosanoic acid and (15,16-3H2) lignoceric acid in cultured skin fibroblasts from patients with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN).J Neurol Sci 71: 359–367.Google Scholar
  42. Uziel G, Bertini E, Rimoldi M, Gambetti M (1990) Italian multicentric dietary therapeutical trial in adrenoleukodystrophy. In Uziel G, Wanders RJA, Cappa M, eds.Adrenoleukodystrophy and Other Peroxisomal Disorders: Clinical, Biochemical, Genetic and Therapeutic Aspects. Amsterdam: Elsevier Science, 163–180.Google Scholar
  43. Van Duyn MA, Moser AB, Brown III FR, Sacktor N, Liu A, Moser HW (1984) The design of a diet restricted in saturated very long chain fatty acids: Therapeutic application in adrenoleukodystrophy.Am J Clin Nutr 40: 277–284.Google Scholar
  44. Van Geel BM, Assies J, Weverling GJ, Barth PG (1994) Predominance of the adrenomyeloneuropathy phenotype of X-linked adrenoleukodystrophy in the Netherlands: A survey of 30 kindreds.Neurology 44: 2343–2346.Google Scholar
  45. Wanders RJA, van Roermund CWT, van Wijland MJA, et al (1988) Direct evidence that the deficient oxidation of very long chain fatty acids in X-linked adrenoleukodystrophy is due to an impaired ability of peroxisomes to activate very long chain fatty acids.Biochem Biophys Res Commun 153: 618–624.Google Scholar
  46. Whitcomb RW, Linehan WR, Knazek RA (1988) Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro.J Clin Invest 81: 185–188.Google Scholar
  47. Zinkham WH, Kickler T, Borel J, Moser HW (1993) Lorenzo's oil and thrombocytopenia in patients with adrenoleukodystrophy.N Engl J Med 328: 1126–1127.Google Scholar

Copyright information

© SSIEM and Kluwer Academic Publishers 1995

Authors and Affiliations

  • H. W. Moser
    • 1
  1. 1.Kennedy Krieger Institute, and the Departments of Neurology and PediatricsJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations